Nutritional supplements that contain curcumin -- a natural anti-inflammatory compound -- may protect the eyes from the ...

Age-related macular degeneration (AMD) is one of the leading causes of vision ... Since AMD is closely linked with aging, some researchers have turned their attention to metformin—a drug better known ...

CHICAGO -- Availability of a bevacizumab biosimilar for ophthalmic use could eliminate a lower-cost treatment option for a ...

Age-related macular degeneration (AMD) is one of the leading causes of vision ... Since AMD is closely linked with aging, some researchers have turned their attention to metformin—a drug better known ...

According to a study presented at the American Academy of Ophthalmology’s annual meeting in Chicago, investigational ...

A new statistical models shed light on why some patients can extend the dosing interval with Eylea (aflibercept) from 8 weeks ...

Roche has released positive topline one-year findings from a Phase IV trial of Vabysmo (faricimab) to treat diabetic macular ...

SOL-1 is now expected to be enrolled and fully randomized by year-end 2024Topline clinical data from SOL-1 are now expected in Q4 2025BEDFORD, ...

Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling ...

This growth in the Age-Related Macular Degeneration market is fueled by ... in research and development investments that lead to more drug approvals and improved reimbursement policies.

Age-related macular degeneration (AMD ... some researchers have turned their attention to metformin—a drug better known for treating type 2 diabetes—because of promising data on its overall ...